189 related articles for article (PubMed ID: 29435360)
41. Abatacept in rheumatoid arthritis: survival on drug, clinical outcomes, and their predictors-data from a large national quality register.
Cagnotto G; Willim M; Nilsson JÅ; Compagno M; Jacobsson LTH; Saevarsdottir S; Turesson C
Arthritis Res Ther; 2020 Jan; 22(1):15. PubMed ID: 31969172
[TBL] [Abstract][Full Text] [Related]
42. Role of anti cyclic citrullinated peptide antibodies in erosive disease in patients with rheumatoid arthritis.
Shankar S; Grover R; Handa R
Indian J Med Res; 2006 Dec; 124(6):689-96. PubMed ID: 17287557
[TBL] [Abstract][Full Text] [Related]
43. Cost per response for abatacept versus adalimumab in patients with seropositive, erosive early rheumatoid arthritis in the US, Germany, Spain, and Canada.
Foo J; Morel C; Bergman M; Baerwald C; Rodriguez-Heredia JM; Marshall A; Polanco-Sánchez C; Postema R
Rheumatol Int; 2019 Sep; 39(9):1621-1630. PubMed ID: 31240388
[TBL] [Abstract][Full Text] [Related]
44. Prospective cohort study of effects of infliximab on rheumatoid factor, anti-cyclic citrullinated peptide antibodies and antinuclear antibodies in patients with long-standing rheumatoid arthritis.
Bruns A; Nicaise-Roland P; Hayem G; Palazzo E; Dieudé P; Grootenboer-Mignot S; Chollet-Martin S; Meyer O
Joint Bone Spine; 2009 May; 76(3):248-53. PubMed ID: 19208451
[TBL] [Abstract][Full Text] [Related]
45. Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis.
Singh JA; Hossain A; Mudano AS; Tanjong Ghogomu E; Suarez-Almazor ME; Buchbinder R; Maxwell LJ; Tugwell P; Wells GA
Cochrane Database Syst Rev; 2017 May; 5(5):CD012657. PubMed ID: 28481462
[TBL] [Abstract][Full Text] [Related]
46. Retention rate of a second line with a biologic DMARD after failure of a first-line therapy with abatacept, tocilizumab, or rituximab: results from the Italian GISEA registry.
Sebastiani M; Venerito V; Bugatti S; Bazzani C; Biggioggero M; Petricca L; Foti R; Bortoluzzi A; Balduzzi S; Visalli E; Frediani B; Manfredi A; Gremese E; Favalli E; Iannone F; Ferraccioli G; Lapadula G;
Clin Rheumatol; 2021 Oct; 40(10):4039-4047. PubMed ID: 33881676
[TBL] [Abstract][Full Text] [Related]
47. Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis.
Quartuccio L; Fabris M; Salvin S; Atzeni F; Saracco M; Benucci M; Cimmino M; Morassi P; Masolini P; Pellerito R; Cutolo M; Puttini PS; De Vita S
Rheumatology (Oxford); 2009 Dec; 48(12):1557-9. PubMed ID: 19789202
[TBL] [Abstract][Full Text] [Related]
48. Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany.
Li N; Betts KA; Messali AJ; Skup M; Garg V
Clin Ther; 2017 Aug; 39(8):1618-1627. PubMed ID: 28729087
[TBL] [Abstract][Full Text] [Related]
49. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
Stevenson M; Archer R; Tosh J; Simpson E; Everson-Hock E; Stevens J; Hernandez-Alava M; Paisley S; Dickinson K; Scott D; Young A; Wailoo A
Health Technol Assess; 2016 Apr; 20(35):1-610. PubMed ID: 27140438
[TBL] [Abstract][Full Text] [Related]
50. Value of ultrasonography as a marker of early response to abatacept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results from the APPRAISE study.
D'Agostino MA; Wakefield RJ; Berner-Hammer H; Vittecoq O; Filippou G; Balint P; Möller I; Iagnocco A; Naredo E; Østergaard M; Boers M; Gaillez C; Van Holder K; Le Bars M;
Ann Rheum Dis; 2016 Oct; 75(10):1763-9. PubMed ID: 26590174
[TBL] [Abstract][Full Text] [Related]
51. Factors contributing to the improvement in J-HAQ after 3 years of treatment with abatacept in biologic-naïve rheumatoid arthritis patients: Interim results of a long-term, observational, multicentre study in Japan (ORIGAMI).
Misaki K; Tanaka E; Inoue E; Tamura N; Hirano F; Taniguchi Y; Sato H; Naniwa T; Oshikawa H; Yoshitama T; Takakubo Y; Suzuki Y; Himeno S; Tsuritani K; Matsumoto S; Yamanaka H; Harigai M
Mod Rheumatol; 2024 May; ():. PubMed ID: 38727535
[TBL] [Abstract][Full Text] [Related]
52. Associations between an expanded autoantibody profile and treatment responses to biologic therapies in patients with rheumatoid arthritis.
Petro AD; Dougherty J; England BR; Sayles H; Duryee MJ; Hunter CD; Kremer JM; Pappas DA; Robinson WH; Curtis JR; Thiele GM; Mikuls TR
Int Immunopharmacol; 2021 Feb; 91():107260. PubMed ID: 33360371
[TBL] [Abstract][Full Text] [Related]
53. Enhanced neutrophil phagocytic capacity in rheumatoid arthritis related to the autoantibodies rheumatoid factor and anti-cyclic citrullinated peptides.
de Siqueira MB; da Mota LM; Couto SC; Muniz-Junqueira MI
BMC Musculoskelet Disord; 2015 Jun; 16():159. PubMed ID: 26123215
[TBL] [Abstract][Full Text] [Related]
54. [Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNFalpha agents failed are associated with response to rituximab in rheumatoid arthritis].
Quartuccio L; Salvin S; Saracco M; Lombardi S; Fabris M; Mansutti E; Maset M; Pellerito S; De Vita S
Reumatismo; 2009; 61(3):182-6. PubMed ID: 19888503
[TBL] [Abstract][Full Text] [Related]
55. Association among anti-citrullinated protein antibody status, erosive disease and healthcare resource utilization in patients with rheumatoid arthritis.
Harrold LR; Shan Y; Connolly SE; Alemao E; Rebello S; Guo L; Kremer JM
Curr Med Res Opin; 2020 Feb; 36(2):337-342. PubMed ID: 31612736
[No Abstract] [Full Text] [Related]
56. High titers of both rheumatoid factor and anti-CCP antibodies at baseline in patients with rheumatoid arthritis are associated with increased circulating baseline TNF level, low drug levels, and reduced clinical responses: a post hoc analysis of the RISING study.
Takeuchi T; Miyasaka N; Inui T; Yano T; Yoshinari T; Abe T; Koike T
Arthritis Res Ther; 2017 Sep; 19(1):194. PubMed ID: 28865493
[TBL] [Abstract][Full Text] [Related]
57. Abatacept reduces disease activity of rheumatoid arthritis independently of modulating anti-citrullinated peptide antibody production.
Yamada H; Tsuru T; Otsuka T; Maekawa M; Harada H; Fukuda T; Tsukamoto H; Maeyama A; Yoshizawa S; Wada K; Nakashima Y; Shono E; Yoshizawa S; Jojima H; Kondo M
Immunol Med; 2020 Jun; 43(2):87-91. PubMed ID: 31994996
[TBL] [Abstract][Full Text] [Related]
58. Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial).
Emery P; Durez P; Dougados M; Legerton CW; Becker JC; Vratsanos G; Genant HK; Peterfy C; Mitra P; Overfield S; Qi K; Westhovens R
Ann Rheum Dis; 2010 Mar; 69(3):510-6. PubMed ID: 19933744
[TBL] [Abstract][Full Text] [Related]
59. Association of rheumatoid arthritis-related autoantibodies with pulmonary function test abnormalities in a rheumatoid arthritis registry.
Huang S; He X; Doyle TJ; Zaccardelli A; Marshall AA; Friedlander HM; Blaustein RB; Smith EA; Cui J; Iannaccone CK; Mahmoud TG; Weinblatt ME; Dellaripa PF; Shadick NA; Sparks JA
Clin Rheumatol; 2019 Dec; 38(12):3401-3412. PubMed ID: 31410660
[TBL] [Abstract][Full Text] [Related]
60. Body mass index as a driver of selection of biologic therapy in rheumatoid arthritis. Results from the US-CLARA study.
Di Carlo M; Salaffi F; Gremese E; Iannone F; Lapadula G; Ferraccioli G;
Eur J Intern Med; 2019 Aug; 66():57-61. PubMed ID: 31113709
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]